Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Denovo Licenses Previously Unknown Use of Cancer Drug for PAH

publication date: Jun 5, 2018

Denovo, a San Diego-Beijing precision medicine company, announced an unusual global license with the Stanford University School of Medicine to develop Denovo's own lead oncology drug for pulmonary arterial hypertension (PAH) and emphysema. Denovo is already testing enzastaurin (DB102) in a Phase III trial for lymphoma. Stanford researchers discovered that enzastaurin is effective against pulmonary hypertension in preclinical models, operating on a different (and previously unknown) target than it does for cancer. Details of the agreement were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital